A Phase 1b Trial of Adaptive Stereotactic Body Radiotherapy in Combination With Durvalumab (MEDI4736), Platinum, and Etoposide in Extensive Stage Small Cell Lung Cancer

This is trial studying the safety of adaptive stereotactic body radiotherapy (SBRT) combined with durvalumab immunotherapy, platinum chemotherapy, and etoposide chemotherapy in platinum refractory extensive stage small cell lung cancer (SCLC).

开始日期2025-12-31

申办/合作机构

University of Maryland Baltimore

[+1]

NCT07001995

/ Not yet recruiting临床2期IIT

A Single-center, Single-arm Phase II Study of Limertinib Plus Carboplatin and Etoposide in EGFR-mutant NSCLC Patients With SCLC Transformation After EGFR-TKI Progression

This single-center, prospective study and aims to evaluate the efficacy and safety of limertinib combined with etoposide and carboplatin in EGFR-mutant NSCLC patients who develop small-cell lung cancer transformation following progression on EGFR-TKI therapy.

开始日期2025-10-01

申办/合作机构

湖南省肿瘤医院

NCT06769126

/ Not yet recruiting临床2期IIT

PRISM: PRecIsion in SCLC Via a Multicohort Study: Randomized Phase II Studies Evaluating Maintenance Durvalumab With or Without Biomarker-Directed Therapy for Extensive Stage Small Cell Lung Cancer (ES-SCLC)

This phase II trial tests how well biomarker tests on patients tumor tissue works in selecting personalized treatments for patients with extensive stage small cell lung cancer (ES-SCLC). Biomarker tests look for certain features in cancer cells that may give doctors more information about what is driving cancer and how to treat it. Based on the biomarker test results, study doctors can determine the subtype of ES-SCLC that study treatments can target. This study also tests different types of maintenance treatment for ES-SCLC with drugs durvalumab, saruparib, ceralasertib or monalizumab. Maintenance treatment is given after initial treatment and is given to help keep the cancer under control and prevent it from getting worse. Immunotherapy with monoclonal antibodies, such as durvalumab and monalizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Saruparib is a PARP inhibitor. PARP is a protein that helps repair damaged deoxyribonucleic acid (DNA). Blocking PARP may prevent cancer cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. Ceralasertib may stop the growth of tumor cells and may kill them by blocking some of the enzymes needed for tumor cell growth. Giving biomarker selected personalized maintenance treatment with durvalumab, saruparib, ceralasertib or monalizumab may work better in treating patients with ES-SCLC.

开始日期2025-09-08

申办/合作机构

SWOG

[+1]

100 项与依托泊苷相关的临床结果

登录后查看更多信息

100 项与依托泊苷相关的转化医学

登录后查看更多信息

100 项与依托泊苷相关的专利（医药）

登录后查看更多信息

35,579

项与依托泊苷相关的文献（医药）

2025-12-31·NMC case report journal

A Primary Spinal Intramedullary Mixed Germ Cell Tumor: A Case Report and Literature Review

Article

作者: SHIMAUCHI-OHTAKI, Hiroya ; HIRATO, Junko ; HORIGUCHI, Keishi ; NAKATA, Satoshi ; HONDA, Fumiaki ; YOKOO, Hideaki ; OYA, Soichi ; GOTO, Yuta ; TOMOMASA, Ran ; NAKAMURA, Shunsuke

Central nervous system germ cell tumors are rare and account for 2% to 3% of all central nervous system tumors in Japan. Here, we report an extremely rare case of a primary spinal intramedullary mixed germ cell tumor. A 33-year-old man presented with a chief report of dysuria and numbness in the right lower extremity. Magnetic resonance imaging revealed a mass lesion on the left side of the intramedullary spinal cord at the Th10-11 vertebral body level with hyperintensity on T2-weighted images, isointensity on T1-weighted images, and uniform contrast in gadolinium. Cerebrospinal fluid examination revealed a few atypical cells. Although tumor removal using the posterior median sulcus approach was attempted, only a biopsy was performed because intraoperative rapid pathology suggested a possible diagnosis of germinoma. Permanent pathology revealed a mixed germ cell tumor (mainly comprising a germinoma with a yolk sac tumor). Postoperatively, cerebrospinal irradiation and 8 courses of the carboplatin and etoposide regimen were administered. No recurrence or new lesions were observed on magnetic resonance imaging at 94 months postoperatively. Our extensive literature search found only 4 cases of a mixed germ cell tumor of primary intramedullary origin in the spinal cord. Most spinal germ cell tumors described in the literature are either germinomas or mature teratomas; however, mixed germ cell tumors can also occur, albeit infrequently. Although additional cases need to be accumulated, our case suggests that yolk sac elements in spinal mixed germ cell tumors might not be directly associated with poor life expectancy.

2025-12-31·JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY

Synthesis, in vitro and in silico studies of a novel chrysin-ferrocene Schiff base with potent anticancer activity via G1 arrest, caspase-dependent apoptosis and inhibition of topoisomerase II

Article

作者: Break, Mohammed Khaled Bin ; Alkahtani, Hamad M. ; Ansari, Siddique Akber ; Alshammari, Maali D. ; Katamesh, Ahmed A. ; Albadari, Najah

A novel chrysin-ferrocene Schiff base (CFSB) was synthesised as a potential anticancer agent. CFSB demonstrated high cytotoxicity against cancer cells with HepG2 (liver) being the most susceptible (IC₅₀ = 3.11 µM). The compound was less toxic towards normal MRC5 cells and exhibited ∼5-fold selectivity towards most cancer cells. CFSB caused G1-phase arrest, induced caspase-dependent apoptosis by increasing Bax/Bcl2 ratio and reduced metastasis by decreasing MMP9 in HepG2. Furthermore, CFSB was inactive against CDK2, EGFR, TrkA and VEGFR, but it strongly inhibited topoisomerase II (IC₅₀ = 20 µM) with potency comparable to etoposide (IC₅₀ = 15 µM), while weak inhibition was observed against tubulin (IC₅₀ = 76 µM). DFT calculations revealed that CFSB had desirable reactivity, while docking indicated high binding affinity with topoisomerase II. Molecular dynamics and MM-GBSA analyses showed that CFSB-topoisomerase II complex was stable with favourable binding energies, while in silico ADMET studies showed drug-like properties for CFSB.

2025-12-31·ANNALS OF MEDICINE

Construction of a novel prognostic model based on lncRNAs-related to DNA damage repair for predicting the prognosis of clear cell renal cell carcinoma

Article

作者: Chen, Peng ; Li, Jian ; Tian, Renli

BACKGROUND:

CcRCC has the characteristics of high aggression, high metastasis, high mortality, wide tumour heterogeneity and variable clinical course. The purpose of this study was to explore the potential value of lncRNAs-related to DNA damage repair (DDR) in predicting the prognosis of ccRCC by construction and verification a novel prognostic model.

METHODS:

RNA-seq data and clinical data of ccRCC were downloaded from public databases. Subsequently, Pearson correlation analysis and differential expression analysis were performed to identify DElncRNAs-related to DDR. Then, through univariate Cox analysis and LASSO analysis, the DElncRNAs-related to DDR associated with prognosis were screened for the construction of novel risk score prognostic model. In addition, functional annotation, tumour mutation burden, immune correlation and drug sensitivity analyses were performed based on risk score to assess the characteristics of patients in different risk score groups.

RESULTS:

Based on univariate Cox analysis and LASSO analysis, four best DElncRNAs-related to DDR were selected. Subsequently, a novel risk score prognostic model based on these four DElncRNAs was constructed through LASSO. Multivariate Cox analysis showed that risk score and age were independent prognostic factors for ccRCC (p < 0.05). Functional enrichment analysis showed that DDR-related biological processes were mainly enriched in the high risk group. The highly mutated genes in the high and low risk groups were the same (VHL, PBRM1 and TTN), but they also had their own unique mutated genes. Pearson correlation analysis showed that the risk score was significantly (p < 0.05) positively correlated with the infiltration degree of CD8 T cells evaluated by six algorithms. In addition, it was found that the high and low risk groups had different sensitivities to the drugs Etoposide, Imatinib, Sorafenib, Bosutinib and Sunitinib.

CONCLUSION:

A novel prognostic model was constructed based on four DElncRNAs-related to DDR. The model has satisfactory accuracy in predicting survival of ccRCC patients.

778

项与依托泊苷相关的新闻（医药）

2025-06-25

·复宏汉霖

从全球首个到本土可及，H药汉斯状®日本小细胞肺癌桥接试验完成首例患者入组

2025年6月25日，复宏汉霖（2696.HK）宣布，公司自主研发的H药汉斯状®（斯鲁利单抗，欧洲商品名：Hetronifly®）在日本开展的桥接临床试验（NCT06812260）完成首例患者入组。 H药汉斯状®是全球首个获批用于一线治疗小细胞肺癌（SCLC）的抗PD-1单抗，已在中国、英国、德国、新加坡、印度等近40个国家和地区获批上市，惠及逾11万患者。NCT06812260研究由关西医科大学附属医院Takayasu Kurata教授担任牵头主要研究者，此次桥接试验旨在评估该产品联合化疗一线治疗广泛期小细胞肺癌（ES-SCLC）在日本患者中的疗效及安全性，为后续H药在日本市场的注册申报奠定基础。肺癌是全球发病率和死亡率最高的癌症，据GLOBOCAN最新数据显示，肺癌是日本发病率第二大高发癌种，2022年日本肺癌新发病例13.6万余例，肺癌死亡病例逾8.3万例，位居该国癌症死亡人数第一[1]。SCLC占肺癌总数的15%-20%，具有恶性程度高、转移早、疾病进展迅速等特点，预后极差。SCLC分为局限期和广泛期，在被确诊为SCLC的日本患者中，约40-50%为ES-SCLC，而其中在确诊后存活5年的患者不足4%[2,3]。此前，复宏汉霖已针对H药汉斯状®用于一线治疗ES-SCLC开展一项随机、双盲、安慰剂对照的国际多中心III期临床研究（ASTRUM-005）。该研究结果于2022年美国临床肿瘤学会（ASCO）年会以口头报告方式首次发布，并于全球四大顶级医学期刊之一的《美国医学会杂志》（JAMA）在线发表，成为全球首个登上JAMA主刊的小细胞肺癌免疫治疗临床研究。2025年美国临床肿瘤学会（ASCO）年会上，ASTRUM-005研究公布研究结束分析结果，截至2024年12月31日（中位随访时间42.4个月），斯鲁利单抗组的4年总生存期（OS）率达21.9%，对照组为7.2%，且安全性可控，进一步夯实了H药能为ES-SCLC患者带来显著的长期生存获益。基于ASTRUM-005研究的优异结果，H药用于治疗ES-SCLC陆续在中国、东南亚多国、欧洲、英国和印度获批用于一线治疗ES-SCLC。复宏汉霖在全球范围内积极推进H药在获批上市进程，目前，公司正在美国开展一项H药对比一线标准治疗阿替利珠单抗用于ES-SCLC的头对头桥接试验，以进一步支持H药在美国的上市申报。复宏汉霖将持续以科学证据为核心，通过本土化开发，推动精准治疗策略的落地，为日本乃至全球患者提供更贴合临床需求的治疗选择。参考文献[1] Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-263. doi:10.3322/caac.21834[2] Sawabata N, Asamura H, Goya T, et al; Japanese Joint Committee for Lung Cancer Registry. Japanese Lung Cancer Registry Study: first prospective enrollment of a large number of surgical and nonsurgical cases in 2002. J Thorac Oncol. 2010 Sep;5(9):1369-75.[3] Oze I, Ito H, Nishino Y, et al. Trends in Small-Cell Lung Cancer Survival in 1993-2006 Based on Population-Based Cancer Registry Data in Japan. J Epidemiol. 2019 Sep 5;29(9):347-353.关于日本桥接研究（NCT06812260）本研究为一项在日本初治广泛期小细胞肺癌（ES-SCLC）患者中进行的单臂、开放、II期的桥接研究。合格的患者将每三周接受一次HLX10（重组人源化抗PD-1单克隆抗体注射液）联合化疗（卡铂-依托泊苷）治疗。主要研究目的为评价HLX10联合化疗在日本初治ES-SCLC患者中的疗效，次要目的为评估HLX10联合化疗的安全性、药代动力学（PK）和免疫原性。主要研究终点为第24周缓解（完全缓解[CR]或部分缓解[PR]）率。次要研究终点包括总生存期（OS）、无进展生存期（PFS）、客观缓解率（ORR）、缓解持续时间（DOR）、生活质量、安全性、PK和免疫原性指标。关于复宏汉霖复宏汉霖（2696.HK）是一家国际化的创新生物制药公司，致力于为全球患者提供可负担的高品质生物药，产品覆盖肿瘤、自身免疫疾病、眼科疾病等领域，已有6款产品在中国获批上市，4款产品在国际获批上市，5个上市申请分别获中国药监局、美国FDA和欧盟EMA受理。自2010年成立以来，复宏汉霖已建成一体化生物制药平台，高效及创新的自主核心能力贯穿研发、生产及商业运营全产业链。公司已建立完善高效的全球创新中心，按照国际药品生产质量管理规范（GMP）标准进行生产和质量管控，不断夯实一体化综合生产平台，其中，公司商业化生产基地已相继获得中国、欧盟和美国GMP认证。复宏汉霖前瞻性布局了一个多元化、高质量的产品管线，涵盖约50个分子，并全面推进基于自有抗PD-1单抗H药汉斯状®的肿瘤免疫联合疗法。截至目前，公司已获批上市产品包括国内首个生物类似药汉利康®（利妥昔单抗）、自主研发的中美欧三地获批单抗生物类似药汉曲优®（曲妥珠单抗，美国商品名：HERCESSI™，欧洲商品名：Zercepac®）、汉达远®（阿达木单抗）、汉贝泰®（贝伐珠单抗）、全球首个获批一线治疗小细胞肺癌的抗PD-1单抗汉斯状®（斯鲁利单抗，欧洲商品名：Hetronifly®）以及汉奈佳®（奈拉替尼）。公司亦同步就19个产品在全球范围内开展30多项临床试验，对外授权全面覆盖欧美主流生物药市场和众多新兴市场。Henlius Doses First Patient in Japanese Bridging Study of Serplulimab for Extensive-Stage Small Cell Lung Cancer Shanghai, China, June 25, 2025 — Shanghai Henlius Biotech, Inc. (2696.HK) announced that the first patient has been dosed in its Japanese bridging study (NCT06812260) of its self-developed innovative anti-PD-1 monoclonal antibody, serplulimab (trade name in Europe: Hetronifly®). Serplulimab is the world’s first anti-PD-1 monoclonal antibody approved for the first-line treatment of small cell lung cancer. It has been approved in nearly 40 countries and regions, including China, the UK, Germany, Singapore, and India, benefiting over 110,000 patients to date. The Japanese bridging studyis, led by Professor Takayasu Kurata of Kansai Medical University Hospital, aims to evaluate the efficacy and safety of serplulimab in combination with chemotherapy for the first-line treatment of extensive-stage SCLC (ES-SCLC) in Japanese patients. This milestone lays a foundation for future regulatory submissions in Japan. Lung cancer is the leading cause of cancer-related deaths worldwide. According to the latest GLOBOCAN data, it is the second most commonly diagnosed cancer in Japan, with over 136,000 new cases and more than 83,000 deaths reported in 2022, making it the country’s top cause of cancer-related mortality[1]. SCLC accounts for 15%–20% of all lung cancers and is characterized by high malignancy, early metastasis, and rapid disease progression, with a dismal prognosis. ES-SCLC accounts for 40%–50% of SCLC cases in Japan, and fewer than 4% of these patients survive five years post-diagnosis[2,3]. Henlius previously conducted ASTRUM-005, a randomized, double-blind, placebo-controlled, global phase 3 study evaluating serplulimab in combination with chemotherapy as a first-line treatment for ES-SCLC. The results were first presented as an oral presentation at the 2022 ASCO Annual Meeting and subsequently published in JAMA, one of the world's top four medical journals—marking the first SCLC immunotherapy study to be published in the journal's main issue. At the 2025 ASCO Annual Meeting, final analysis results of the study were presented: as of December 31, 2024 (median follow-up: 42.4 months), the 4-year overall survival (OS) rate was 21.9% in the serplulimab group versus 7.2% in the control group, with a manageable safety profile, further underscoring the long-term survival benefit of serplulimab for ES-SCLC patients. Driven by the strong clinical data from ASTRUM-005, serplulimab has been approved for first-line treatment of ES-SCLC in China, Europe, UK, India and multiple Southeast Asian countries. In parallel, Henlius is conducting a head-to-head bridging study in the U.S. comparing serplulimab to the current standard-of-care, atezolizumab, to support its potential U.S. regulatory submission. Henlius remains committed to science-based development and will continue advancing localized strategies to enable precision treatment, aiming to deliver clinically relevant therapeutic options for patients in Japan and around the world. About NCT06812260 This is a single-arm, open-label, phase 2 bridging trial conducted in Japanese patients with previously untreated extensive-stage small-cell lung cancer (ES-SCLC). Eligible patients will be administrated once every three weeks with HANSIZHUANG in combination with chemotherapy (carboplatin-etoposide). The primary objective of the study is to evaluate the efficacy of HANSIZHUANG in combination with chemotherapy in Japanese patients with previously untreated ES-SCLC. The secondary objectives are to evaluate the safety, pharmacokinetics, and immunogenicity of HANSIZHUANG in combination with chemotherapy. The primary endpoint is the response (complete response (CR) or partial response (PR)) rate at week 24. Secondary endpoints include overall survival (OS), progression-free survival (PFS), objective response rate (ORR), duration of response (DOR), quality of life, safety, pharmacokinetics, and immunogenicity parameters.About HenliusHenlius (2696.HK) is a global biopharmaceutical company with the vision to offer high-quality, affordable and innovative biologic medicines for patients worldwide with a focus on oncology, autoimmune diseases and ophthalmic diseases. Up to date, 6 products have been launched in China, 4 have been approved for marketing in overseas markets, and 5 marketing applications have been accepted for review in China, the U.S. and the EU, respectively. Since its inception in 2010, Henlius has built an integrated biopharmaceutical platform with core capabilities of high-efficiency and innovation embedded throughout the whole product life cycle including R&D, manufacturing and commercialization. It has established global innovation centre and Shanghai-based commercial manufacturing facilities certificated by China, the EU and U.S. GMP.Henlius has pro-actively built a diversified and high-quality product pipeline covering about 50 molecules and has continued to explore immuno-oncology combination therapies with proprietary HANSIZHUANG (anti-PD-1 mAb) as the backbone. To date, the company's launched products include HANLIKANG (rituximab), the first China-developed biosimilar, HANQUYOU (trastuzumab, trade name: HERCESSI™ in the U.S., Zercepac® in Europe), a China-developed mAb biosimilar approved in China, Europe and U.S., HANDAYUAN (adalimumab), HANBEITAI (bevacizumab), HANSIZHUANG (serplulimab, trade name: Hetronifly® in Europe), the world’s first anti-PD-1 mAb for the first-line treatment of SCLC, and HANNAIJIA (neratinib). What’s more, Henlius has conducted over 30 clinical studies for 19 products, expanding its presence in major markets as well as emerging markets.联系方式媒体：PR@Henlius.com投资者：IR@Henlius.com喜欢本文内容点击下方按钮·分享 ·收藏 ·点赞 ·在看

ASCO会议临床结果临床3期上市批准免疫疗法

2025-06-23

·ioncology

EHA & ICML中国强音丨赵维莅教授团队LBA研究引领淋巴瘤治疗新方向，多项成果亮相国际舞台

点击蓝字关注我们编者按2025年欧洲血液学会（EHA）年会与国际恶性淋巴瘤会议（ICML）相继在米兰与卢加诺召开，聚焦全球血液肿瘤学的最新进展。上海交通大学医学院附属瑞金医院赵维莅教授团队携多项研究成果重磅亮相国际舞台，全面覆盖弥漫大B细胞淋巴瘤、滤泡性淋巴瘤、套细胞淋巴瘤及外周T细胞淋巴瘤等多个亚型，充分展现中国团队在机制探索、精准分型、免疫治疗及真实世界研究等方面的持续深耕与系统布局。其中，关于泽布替尼联合来那度胺和利妥昔单抗（ZR2）治疗高龄体弱DLBCL患者的PEARL研究更是入选ICML大会LBA摘要（Latest Breakthrough Abstract）报告，显示其与标准减量化疗（R-miniCHOP）疗效相当，有望成为化疗替代方案，标志着中国原创治疗策略的重大突破。GUIDANCE-02研究探索基于遗传亚型指导的一线个体化治疗模式，也正在国内多中心稳步推进，反映出从科研设计到临床转化的高质量闭环。本期特整理这些研究的核心亮点，带您一览淋巴瘤领域的前沿进展。弥漫大B细胞淋巴瘤01摘要号：ICML#LBA2标题：Zanubrutinib plus lenalidomide and rituximab versus R-miniCHOP in unfit or frail patients with newly diagnosed diffuse large B-cell lymphoma aged 70 years or older中文标题：泽布替尼联合来那度胺和利妥昔单抗与R-miniCHOP用于治疗70岁及以上新诊断不适合强化治疗或虚弱弥漫大B细胞淋巴瘤患者的对比研究类型：LBA第一作者：许彭鹏研究结论：本研究（PEARL）结果显示，ZR2方案（泽布替尼联合来那度胺和利妥昔单抗）在完全缓解率上与R-miniCHOP相当，且两组基线特征平衡，提示ZR2方案有望成为70岁及以上新诊断不适合强化治疗或虚弱弥漫大B细胞淋巴瘤（DLBCL）患者一种有效且潜在更安全的无化疗治疗选择。02摘要号：ICML#OT05（在研临床试验）标题：GUIDANCE-02: A multi-center randomized phase 3 study of genetic subtype-guided immunochemotherapy in diffuse large B-cell lymphoma中文标题：GUIDANCE-02研究：一项基于遗传亚型指导免疫化疗治疗弥漫大B细胞淋巴瘤的多中心、随机、III期临床研究类型：口头报告第一作者：赵维莅研究进展：GUIDANCE-02是一项正在进行的、多中心、随机、III期临床研究，旨在评估基于遗传亚型指导的免疫化疗方案（R-CHOP-X）相较于标准R-CHOP在新诊断的中高危弥漫大B细胞淋巴瘤（DLBCL）患者中的疗效和安全性。研究采用38基因分类算法“LymphPlex” 对患者进行分型，并根据不同亚型个性化添加靶向药物（如奥布替尼、来那度胺或地西他滨）。主要终点为无进展生存期（PFS），目前已在中国58家中心已经完成1100例入组，结果有望进一步推动DLBCL的精准治疗策略。03摘要号：EHA#PS1956标题：INTERIM ANALYSIS OF POMALIDOMIDE PLUS RITUXIMAB, IFOSFAMIDE, CARBOPLATIN, AND ETOPOSIDE (PR-ICE) IN RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: A PHASE I/II STUDY (PRIDE STUDY)中文标题：泊马度胺联合利妥昔单抗、异环磷酰胺、卡铂和依托泊苷（PR-ICE）治疗复发/难治性弥漫性大B细胞淋巴瘤的Ⅰ/Ⅱ期研究的中期分析（PRIDE研究）类型：壁报第一作者：许彭鹏研究结论：复发/难治性弥漫大B细胞淋巴瘤（R/R DLBCL）治疗选择有限，预后较差。本研究显示，PR-ICE方案在R/R DLBCL患者中展现出较高的疗效与可接受的安全性。泊马度胺与R-ICE联合的确定最大耐受剂量（MTD）在临床上诱导了显著的完全缓解率。这些结果支持将PR-ICE作为R/R DLBCL挽救治疗方案进行进一步研究。04摘要号：EHA#PF916标题：POSITRON EMISSION TOMOGRAPHY-ADAPTED THERAPY IN LOW-RISK DIFFUSE LARGE B-CELL LYMPHOMA: 4-YEAR RESULTS OF A RANDOMIZED, PHASE III, NON-INFERIORITY TRIAL中文标题：低危弥漫大B细胞淋巴瘤PET-CT调整的治疗：一项随机、III期、非劣效性试验的4年随访结果类型：壁报第一作者：施晴研究结论：本研究显示，对于中期PET-CT阴性的低危、非巨块型弥漫大B细胞淋巴瘤（DLBCL）患者，4个周期的R-CHOP方案加4个周期的利妥昔单抗方案可提供与6个周期的R-CHOP方案加2个周期的利妥昔单抗方案相当的长期临床疗效。该PET-CT调整性治疗策略在保证持续缓解的同时，有望减少化疗强度，为低危DLBCL的治疗管理提供了新思路。05摘要号：ICML#294标题：Clinical practice pattern and outcomes in DLBCL with distinct genetic subtypes: a large-scale real-world study from China中文标题：不同基因亚型弥漫大B细胞淋巴瘤的临床实践模式与治疗结局：中国大规模真实世界研究类型：壁报第一作者：许彭鹏研究结论：本项中国大规模真实世界研究显示，弥漫大B细胞淋巴瘤（DLBCL）具有高度遗传异质性，不同分子亚型在治疗模式和临床结局上呈现出显著差异。尽管R-CHOP仍为主要一线方案，但部分患者接受了靶向治疗、CAR-T或自体移植等强化治疗。研究结果为推进基因分型指导下的精准治疗提供了重要依据，有望优化DLBCL的治疗策略与预后管理。06摘要号：EHA#PS2162标题：HIGH EFFICACY AND SAFETY OF A NOVEL ANTI-CD20 CAR-T CELL THERAPY, LY007 IN RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA中文标题：新型抗CD20 CAR-T细胞疗法LY007在复发或难治性B细胞非霍奇金淋巴瘤中的高效性和良好安全性类型：壁报第一作者：盛凌霜研究结论：LY007在最高剂量水平（DL3）下显示出良好的安全性、可观的疗效及稳健的药代动力学特征，未观察到剂量限制性毒性（DLT）、神经毒性或≥3级细胞因子释放综合征 (CRS)。LY007的生物利用度 (BOR) 达到91.7%，包括高肿瘤负荷、既往接受过CD19 CAR-T治疗和自体干细胞移植 (ASCT) 的患者。07摘要号：EHA#PF971标题：SAFETY AND EFFECTIVENESS OF BRENTUXIMAB VEDOTIN IN CHINESE CD30-POSITIVE LYMPHOMA ADULTS: AN INTERIM ANALYSIS FROM BRAVE STUDY中文标题：维布妥昔单抗在中国CD30阳性淋巴瘤成人患者中的安全性和有效性：BRAVE研究的中期分析类型：壁报第一作者：蔡铭慈研究结论：本研究结果进一步支持维布妥昔单抗(BV)联合化疗在CD30阳性淋巴瘤治疗中疗效确切、耐受性良好，是一种有价值的治疗选择。BRAVE研究仍在持续进行中，后续将公布长期随访结果。套细胞淋巴瘤01摘要号：EHA#PS1969标题：ORELABRUTINIB PLUS BENDAMUSTINE-RITUXIMAB (OBR) VERSUS BENDAMUSTINE-RITUXIMAB (BR) IN TRANSPLANT-INELIGIBLE, INTERMEDIATE- TO HIGH-RISK MANTLE CELL LYMPHOMA (MCL)中文标题：奥布替尼联合苯达莫司汀-利妥昔单抗（OBR）与苯达莫司汀-利妥昔单抗（BR）治疗不适合移植的中高危套细胞淋巴瘤（MCL）患者的对比研究类型：壁报第一作者：王黎研究结论：免疫化疗仍是套细胞淋巴瘤（MCL）的标准治疗方案，但携带高危特征，如TP53突变、母细胞样或多形性组织学亚型，或高MCL国际预后指数[MIPI]评分（伴Ki-67增殖指数[Ki-67%]>30%）的患者预后较差。本研究初步数据表明，OBR方案较BR方案可减少高危MCL患者的疾病进展事件。后续将公布疗效、安全性及生物标志物的更多研究结果。滤泡性淋巴瘤01摘要号：EHA#PS1906标题：NATIONWIDE SURVEY OF THE JOURNEY OF PATIENTS LIVING WITH FOLLICULAR LYMPHOMA IN CHINA: REAL-WORLD INSIGHTS AND ANALYSIS中文标题：中国滤泡性淋巴瘤患者诊疗旅程的全国性调研：真实世界见解与分析类型：壁报第一作者：赫洋研究结论：本研究首次在全国范围内系统调研了中国滤泡性淋巴瘤（FL）患者的真实诊疗旅程，发现患者在不同治疗阶段的目标和需求存在明显差异，初治阶段以治愈和延长生存为主，复发后则更关注避免复发和治疗选择；影响治疗决策的主要因素包括疗效、安全性及经济负担；信息获取渠道也随病程进展由网络转向专业医疗人员。该研究为优化患者管理、制定个体化支持策略提供了重要的真实世界依据。02摘要号：EHA#PF897、ICML#178标题：CLINICAL CHARACTERISTICS AND MOLECULAR HETEROGENEITY IN FOLLICULAR LYMPHOMA WITH EXTRANODAL INVOLVEMENT中文标题：结外受累滤泡性淋巴瘤患者的临床特征与分子异质性分析类型：壁报第一作者：李悦驰研究结论：本研究发现，多发结外侵犯（ENI）是滤泡性淋巴瘤患者接受利妥昔单抗联合化疗时的重要不良预后因素，相关基因突变（如KMT2D、CREBBP、CARD11、STAT6）及免疫通路下调可能在其中发挥作用；但在接受利妥昔单抗联合来那度胺（R2）免疫治疗的患者中，ENI对预后的负面影响不再显著，提示免疫治疗有望克服ENI带来的不良影响，并为机制导向的个体化治疗提供了新的思路。外周T细胞淋巴瘤01摘要号：ICML#62标题：A Phase II Trial of Pembrolizumab Concurrent with Radiotherapy for Frail Patients with Newly Diagnosed Early-stage Natural Killer/T-cell Lymphoma (IELSG50)中文标题：帕博利珠单抗联合放疗治疗新诊断早期虚弱自然杀伤/T细胞淋巴瘤患者的Ⅱ期临床试验（IELSG50）类型：口头报告第一作者：钟慧娟研究结论：NK/T细胞淋巴瘤（NKTCL）是一种侵袭性极高的淋巴瘤，常与EB病毒感染和免疫检查点高表达相关。对于不适合化疗的患者，治疗选择有限。免疫检查点抑制剂已在复发/难治性NKTCL中展现出疗效。本研究显示，帕博利珠单抗联合放疗在新诊断、早期、虚弱NKTCL患者中展现出良好的疗效和安全性，尤其适用于中高危患者。免疫检查点抑制剂有望作为早期NKTCL一线治疗的替代策略。02摘要号：ICML#163标题：Tazemetostat plus Amdizalisib in Relapsed/Refractory Peripheral T-cell Lymphoma Patients with Diverse Genomic Signatures: Results from a Phase 2 Study中文标题：他泽司他联合Amdizalisib 治疗具有不同基因组特征的复发或难治性外周T细胞淋巴瘤患者：一项Ⅱ期研究结果类型：口头报告第一作者：程澍研究结论：外周T细胞淋巴瘤（PTCL）是一类侵袭性强、异质性高的T细胞肿瘤，目前缺乏有效治疗手段。不同基因特征的患者对治疗的反应存在差异。本研究显示，他泽司他联合Amdizalisib在复发/难治性PTCL中表现出良好疗效，尤其在血管免疫母细胞T细胞淋巴瘤（AITL）亚型中缓解率较高。TET2和RHOA共突变的患者可能预示更佳治疗反应。后续需更大样本进一步验证这些发现。专家简介赵维莅教授上海交通大学医学院附属瑞金医院主任医师，教授，博士生导师国家杰出青年科学基金获得者教育部长江学者特聘教授科技部万人计划领军人才百千万人才工程国家级人选上海交通大学医学院附属瑞金医院副院长上海市重中之重临床医学中心主任上海血液学研究所所长中华医学会血液学分会副主任委员，淋巴细胞疾病学组组长中国病理生理学会理事，实验血液学专委会副主任委员中国临床肿瘤协会抗淋巴瘤联盟副主席致力于淋巴细胞恶性疾病的临床和基础研究，以通讯/第一作者在《The New England Journal of Medicine 》《CANCER CELL》、《NATURE GENETICS》、《BLOOD》《LANCET HAEMATOL》、《SIGNAL TRANSDUCT TARGET THER》、《J HEMATOL ONCOL》等国际权威杂志发表文章110余篇，总影响因子超过1500。相关成果以第一完成人获国家科学技术进步奖二等奖1项，省部级一等奖6项，获国家发明专利15项，主持国家科技部重点研发计划、863 重大项目、国家自然科学基金重点项目多项。先后荣获 “全国卫生系统先进工作者”、“全国三八红旗手”、中国青年女科学家奖、EBMT青年领袖奖、吴阶平医药创新奖、谈家桢生命科学奖、上海市科技精英等多项荣誉（来源：《肿瘤瞭望–血液时讯》编辑部）声明凡署名原创的文章版权属《肿瘤瞭望》所有，欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。

临床结果免疫疗法临床3期细胞疗法

2025-06-20

·恒瑞医药

恒瑞医药EZH2抑制剂SHR2554与免疫治疗、ADC等联合治疗实体瘤获批临床

近日，恒瑞医药及子公司苏州盛迪亚生物医药有限公司、上海恒瑞医药有限公司、上海盛迪医药有限公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，批准开展SHR2554联合或不联合阿得贝利单抗或瑞拉芙普-α注射液（SHR-1701）联合或不联合瑞康曲妥珠单抗或SHR-A1904或SHR-A2102，或联合醋酸阿比特龙或二代AR抑制剂用于实体瘤的临床研究。Zeste基因增强子同源物2 (EZH2，Enhancer of Zeste Homolog 2)是组蛋白甲基化转移酶的核心成分，通过催化组蛋白H3氨基末端第27位赖氨酸发生三甲基化(H3K27Me3)来控制对细胞的增殖、分化至关重要的基因转录。EZH2功能失调与多种癌症相关，包括胃癌、非小细胞肺癌等，因此成为抗癌药物的理想靶点[1]。SHR2554是恒瑞医药开发的新型口服EZH2抑制剂，拟用于恶性肿瘤的治疗。2024年10月，SHR2554片的药品上市许可申请获国家药监局受理，且被纳入优先审评品种公示，适应症为：用于既往接受过至少1线系统性治疗的复发或难治外周T细胞淋巴瘤（PTCL）。2023年2月，恒瑞医药将自主研发的抗癌创新药EZH2抑制剂SHR2554在大中华区以外的全球范围内开发、生产及商业化的独家权利许可给美国Treeline Biosciences公司。阿得贝利单抗是恒瑞医药自主研发的人源化抗PD-L1单克隆抗体，能通过特异性结合PD-L1分子从而阻断导致肿瘤免疫耐受的PD-1/PD-L1通路，重新激活免疫系统的抗肿瘤活性，从而达到治疗肿瘤的目的。阿得贝利单抗注射液（商品名：艾瑞利®）已于2023年获批上市，获批的适应症为与卡铂和依托泊苷联合用于广泛期小细胞肺癌患者的一线治疗。公司现有多项阿得贝利单抗注射液临床研究正在进行，以评估其在非小细胞肺癌、小细胞肺癌、肝细胞癌、胆道癌、晚期胃癌及食管癌等多种实体瘤中的抗肿瘤作用。瑞拉芙普-α注射液（SHR-1701）是恒瑞医药自主研发的抗PD-L1/TGF-βRII双功能融合蛋白，可以促进效应性T细胞的活化，同时还可有效改善肿瘤微环境中的免疫调节作用，最终有效促进免疫系统对于肿瘤细胞的杀伤。2024年9月，瑞拉芙普-α注射液上市许可申请获国家药监局受理，适应症为本品联合氟尿嘧啶类和铂类药物用于局部晚期不可切除、复发或转移性胃及胃食管结合部腺癌的一线治疗。经查询，国内外尚无同类产品获批上市。瑞拉芙普-α注射液在胃癌或胃食管结合部癌等治疗领域现有多项临床研究正在进行。注射用瑞康曲妥珠单抗是恒瑞医药自主研发的、以HER2为靶点的抗体偶联药物（ADC，antibody-drug conjugates），可通过与HER2表达的肿瘤细胞结合并内吞，在肿瘤细胞溶酶体内通过蛋白酶剪切释放毒素，诱导细胞周期阻滞从而诱导肿瘤细胞凋亡。今年5月，注射用瑞康曲妥珠单抗（商品名：艾维达®）上市，用于治疗存在HER2（ERBB2）激活突变且既往接受过至少一种系统治疗的不可切除的局部晚期或转移性非小细胞肺癌（NSCLC）成人患者。这是国内首个获批用于HER2突变NSCLC患者的中国自主研发抗体偶联药物（ADC）。瑞康曲妥珠单抗目前在肺癌、乳腺癌、结直肠癌、胃癌或胃食管结合部腺癌、胆道癌以及上皮性卵巢癌、输卵管癌或原发性腹膜癌、宫颈癌治疗领域的8项适应症均获国家药品监督管理局突破性疗法认定，未来有望造福更广泛的患者群体。SHR-A1904是恒瑞医药自主研发的靶向Claudin18.2的抗体偶联药物（ADC），其有效载荷是拓扑异构酶抑制剂（TOPOi），通过与肿瘤细胞表面的靶抗原结合，使得药物被内吞进入细胞后释放小分子毒素杀伤肿瘤细胞。目前该产品正在中国、美国、澳大利亚进行临床试验。SHR-A2102为恒瑞医药自主研发的靶向Nectin-4的抗体偶联药物（ADC），其有效载荷是拓扑异构酶Ⅰ抑制剂（TOPi）。多项研究表明Nectin-4在肿瘤中的高表达与肿瘤的发展和不良预后密切相关。注射用SHR-A2102正在中国进行多项临床试验，涵盖尿路上皮癌、食管癌、非小细胞肺癌、晚期妇科恶性肿瘤等多项适应症。2024年12月，注射用SHR-A2102单药治疗既往含铂化疗和PD-(L)1抑制剂治疗失败的局部晚期或转移性尿路上皮癌被国家药品监督管理局药品审评中心纳入突破性治疗品种名单。2024年4月，该产品用于治疗晚期尿路上皮癌适应症已获得美国食品和药物监督管理局（FDA）授予快速通道资格（fast track designation, FTD）。参考文献：1.Yuan R, Du W, Guo W. EZH2: a novel target for cancer treatment. J Hematol Oncol. 2020;13(1):104. doi:10.1186/s13045-020-00937-8.声明：1.本新闻旨在分享研发前沿资讯，仅供医疗卫生专业人士参阅，非广告用途。2.瑞医药不对任何药品和/或适应症作推荐。3.本新闻中涉及的信息仅供参考，请遵从医生或其他医疗卫生专业人士的意见或指导。医疗卫生专业人士作出的任何与治疗有关的决定应根据患者的具体情况并遵照药品说明书。撰稿：程梦真排版：程梦真责编：王玲往期精选| 研发创新 |恒瑞创新药瑞坦宁®获批，用于预防成人高度致吐性化疗引起的急性和迟发性恶心呕吐| 国际化 |恒瑞医药再次与德国默克集团达成合作，推进辅助生殖领域口服GnRH拮抗剂商业化落地恒瑞医药与默沙东就Lp(a)抑制剂HRS-5346签订独家许可协议| 重磅奖项 |捷报！恒瑞医药创新药海曲泊帕乙醇胺片（恒曲®）专利荣获中国专利金奖喜报！恒瑞医药荣获2023年度国家科技进步奖| 社会公益 |“健康中国行·重走长征路”项目启动仪式圆满举行！恒瑞提供公益支持，助力健康中国恒瑞医药集团向中国扶贫基金会捐赠3000万设立“健康帮扶基金”

上市批准优先审批抗体药物偶联物免疫疗法申请上市

100 项与依托泊苷相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00125	依托泊苷	L01CB01	DB00773

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
膀胱癌	日本	Clinigen Ltd.	1987-04-30
白血病	日本	Clinigen Ltd.	1987-04-30
淋巴瘤	日本	Nippon Kayaku Co., Ltd.	1987-03-31
卵巢癌	日本	Nippon Kayaku Co., Ltd.	1987-03-31
宫颈癌	日本	Nippon Kayaku Co., Ltd.	1987-03-31
小细胞肺癌	美国	Corden Pharma Latina SpA	1983-11-10
睾丸肿瘤	美国	Corden Pharma Latina SpA	1983-11-10

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
铂耐药性卵巢癌	临床3期	中国	江苏恒瑞医药股份有限公司	2019-08-16
原发部位不明恶性肿瘤	临床3期	美国	Pharmacia & Upjohn, Inc.	2003-09-01
原发部位不明恶性肿瘤	临床3期	美国	Eli Lilly & Co.	2003-09-01
原发部位不明恶性肿瘤	临床3期	美国	AstraZeneca PLC	2003-09-01
广泛期小细胞肺癌	临床3期	美国	GSK Plc	2001-04-01
广泛期小细胞肺癌	临床3期	中国	GSK Plc	2001-04-01
广泛期小细胞肺癌	临床3期	奥地利	GSK Plc	2001-04-01
广泛期小细胞肺癌	临床3期	比利时	GSK Plc	2001-04-01
广泛期小细胞肺癌	临床3期	巴西	GSK Plc	2001-04-01
广泛期小细胞肺癌	临床3期	保加利亚	GSK Plc	2001-04-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02262325 (CTgov)	临床2期	非小细胞肺癌IIIA期 \| 非小细胞肺癌IIIB期 \| 复发性非小细胞肺癌 ... 更多	21	3-dimensional conformal radiation therapy+etoposide+cisplatin	廠鑰遞窪襯壓艱膚獵夢 = 範窪築鹹蓋築構壓網範襯築鏇齋構簾積範廠廠 (獵餘獵淵餘獵衊餘鏇齋, 積積鬱遞膚鬱淵窪遞積 ~ 壓網網餘獵製範鹽壓築) 更多	-	2025-06-12
NCT03811002 (NRG-LU005, CTgov)	临床3期	局限期小细胞肺癌	544	Intensity-Modulated Radiation Therapy+Etoposide+Carboplatin+cisplatin (Arm I (Chemotherapy, Radiation Therapy))	糧糧積積遞鏇築襯構鹹(醖壓鹽積窪鏇襯壓獵齋) = 繭觸窪鏇衊窪顧鏇鹹壓願齋衊鑰範觸糧壓範餘 (築蓋繭繭觸網選窪觸膚, 艱襯夢鬱獵積構膚襯鏇 ~ 遞觸醖鹹構鬱憲鹽選糧) 更多	-	2025-06-12
				Intensity-Modulated Radiation Therapy+Etoposide+Carboplatin+cisplatin+Atezolizumab (Arm II (Chemotherapy, Radiation Therapy, Atezolizumab))	糧糧積積遞鏇築襯構鹹(醖壓鹽積窪鏇襯壓獵齋) = 壓夢淵壓窪繭膚齋膚艱願齋衊鑰範觸糧壓範餘 (築蓋繭繭觸網選窪觸膚, 觸鹹膚襯餘願蓋衊糧鹹 ~ 淵淵遞願觸繭範觸蓋選) 更多
NCT00476190 (CTgov)	临床2期	成人急性淋巴细胞白血病	112	Radiation Therapy+PEG-Asparaginase+Etoposide+doxorubicin+Hydrocortisone Sodium Succinate+6-MP+Methotrexate+Cytarabine+Methylprednisone+Cyclophosphamide+Imatinib+Dexamethasone+E. coli Asparaginase+Vincristine (Pre-amendment Cohort, 2500 IU/m2 q2 Weeks)	艱構醖選餘醖製獵鏇鏇 = 製選構範衊膚壓蓋積選糧築糧齋觸鏇憲窪齋淵 (鑰獵襯糧齋範壓窪遞醖, 鹽憲製艱製廠網簾繭齋 ~ 觸淵糧廠鹹窪構衊觸獵) 更多	-	2025-06-12
				Radiation Therapy+PEG-Asparaginase+Etoposide+Doxorubicin+Hydrocortisone Sodium Succinate+6-MP+Methotrexate+Cytarabine+Methylprednisone+Cyclophosphamide+Imatinib+Dexamethasone+E. coli Asparaginase+Vincristine (Post-amendment Cohort, 2000 IU/m2 q3 Weeks)	艱構醖選餘醖製獵鏇鏇 = 繭製遞醖醖繭餘襯鏇鏇糧築糧齋觸鏇憲窪齋淵 (鑰獵襯糧齋範壓窪遞醖, 艱蓋膚憲糧廠夢齋鬱顧 ~ 糧範壓鏇鑰製蓋壓膚選) 更多
ASCO2025	N/A	小儿眼内视网膜母细胞瘤	-	Vincristine + Topotecan	鏇鬱壓選觸遞鏇醖餘淵(艱製艱鬱製構選夢鏇獵) = 鬱醖構製憲襯蓋鹽製觸淵廠觸餘構艱遞糧夢醖 (網鑰範醖築糧壓鑰憲廠 ) 更多	不佳	2025-05-30
				High Dose Carboplatin + Etoposide + Vincristine	鏇鬱壓選觸遞鏇醖餘淵(艱製艱鬱製構選夢鏇獵) = 襯壓醖築願衊遞遞鏇築淵廠觸餘構艱遞糧夢醖 (網鑰範醖築糧壓鑰憲廠 ) 更多
ASCO2025	临床2期	高风险神经母细胞瘤	34	HITS (Irinotecan, Temozolomide, Naxitamab, GM-CSF)	鑰遞蓋選餘積糧觸願簾(選鹽夢簾齋製夢餘鹹蓋) = 製齋膚範範衊構壓壓壓鏇餘窪糧艱蓋夢衊顧願 (構簾壓築遞膚糧廠鑰蓋 ) 更多	积极	2025-05-30
				NICE (Naxitamab, GM-CSF, Ifosfamide, Carboplatin, Etoposide)	鑰遞蓋選餘積糧觸願簾(選鹽夢簾齋製夢餘鹹蓋) = 簾憲夢夢窪淵積顧憲選鏇餘窪糧艱蓋夢衊顧願 (構簾壓築遞膚糧廠鑰蓋 ) 更多
PB3418 (EHA2025)	N/A	多发性骨髓瘤	75	G-CSF alone	蓋醖鬱鹹鏇淵簾膚鑰繭(選觸鹽廠簾衊觸積壓蓋) = 繭餘淵壓淵蓋窪鹽製鏇構遞鑰醖糧鬱餘積鹽築 (廠鏇憲鏇膚糧衊窪廠醖, 4.56 ~ 6.18)	积极	2025-05-14
				Etoposide + G-CSF	蓋醖鬱鹹鏇淵簾膚鑰繭(選觸鹽廠簾衊觸積壓蓋) = 製壓鏇簾顧襯糧選夢窪構遞鑰醖糧鬱餘積鹽築 (廠鏇憲鏇膚糧衊窪廠醖, 10.56 ~ 18.94) 更多
PB3408 (EHA2025)	N/A	造血干细胞移植	57	Carboplatin, Etoposide, and Melphalan (CEM) regimen	繭夢餘觸艱廠廠製衊繭(積築醖糧積淵襯繭蓋鏇) = 範憲製淵鏇憲簾壓艱簾簾醖糧鑰艱淵廠構鑰憲 (鏇夢窪餘膚廠窪網顧繭 ) 更多	积极	2025-05-14
NCT03980925 (GETNE T1913, CTgov)	临床2期	胃肠道神经内分泌肿瘤 \| 胃肠胰神经内分泌肿瘤	37	Nivolumab+Etoposide+Carboplatin	齋鏇築憲簾廠膚鹽繭築 = 願築顧積淵鬱網壓餘衊夢襯獵積壓獵餘簾鹽獵 (鏇鹹糧鏇醖繭襯衊簾廠, 獵膚遞壓艱製築糧獵範 ~ 繭憲糧齋夢衊壓襯醖遞) 更多	-	2025-01-13
NCT02705508 (Pubmed \| Hematology) 人工标引	临床2期	结外NK-T细胞淋巴瘤一线	34	PEG (pegaspargase, etoposide, gemcitabine)	壓憲鏇選廠窪夢廠齋範(鏇壓鬱積窪艱顧鬱衊繭) = 願衊鹽壓範鏇鏇齋膚鏇繭獵鬱顧鏇醖艱鹹築夢 (繭築窪網簾艱願糧鹽膚 ) 更多	积极	2024-12-31
NCT04923776 (CTgov)	临床2期	广泛期小细胞肺癌	2	Stereotactic Body Radiation Therapy (SBRT)+Etoposide+Carboplatin+Atezolizumab	衊襯積範壓構壓鬱廠窪(獵觸餘鹽積願衊範築築) = 範簾築構鏇製選齋簾簾衊憲築鏇醖餘糧艱衊製 (膚築艱醖艱構簾觸窪膚, 範齋夢簾窪鏇選構艱顧 ~ 鏇觸糧鏇餘鏇糧醖築範) 更多	-	2024-12-30